FNP Adult Immunization Practice Questions

When two live attenuated vaccines like varicella and MMR are not administered on the exact same day, they must be separated by at least 28 days. Administering the MMR vaccine today, only two weeks after the varicella dose, would blunt the immune response to the MMR vaccine. Deferring for only one week still falls short of the required 28-day minimum interval. Therefore, the APRN must wait an additional two weeks to ensure adequate immunogenicity and effective primary prevention.

During the initial prenatal visit, an indirect Coombs test is required for Rh-negative women to screen for maternal alloimmunization, especially given her history of a previous spontaneous abortion. Option B is correct because establishing baseline antibody status directs further management. Option A is incorrect because Rho(D) immune globulin is not indicated at 10 weeks unless bleeding occurs, and baseline antibody status must be known first. Option C is overly invasive and carries unnecessary fetal risk at this early stage. Option D is incorrect because delaying the initial antibody screen misses the opportunity to identify pre-existing sensitization, which requires close monitoring throughout the pregnancy.

The patient is Rubella IgG negative, indicating she is non-immune. Because the MMR vaccine is a live-attenuated virus, it is contraindicated during pregnancy due to the theoretical risk of congenital rubella syndrome. The correct action is to advise avoiding sick contacts, especially since she has a toddler in daycare, and administer the vaccine immediately postpartum. Option A is incorrect because live vaccines are contraindicated. Option C is unnecessary; an IgG negative result simply means a lack of immunity, not an indeterminate acute state requiring IgM testing. Option D is incorrect as immune globulin is not standard prophylaxis for rubella non-immunity in pregnancy.

Adhering to strict minimum intervals is crucial when administering vaccines to ensure long-term efficacy. For a standard two-dose HPV schedule, the minimum interval required between the first and second dose is exactly five months, although six to twelve months is routinely recommended for optimal immune response. Administering the second dose at only three months would result in an invalid dose that must eventually be repeated. Therefore, the provider must defer the vaccine and schedule it for three months from now to meet the six-month mark. Option A is incorrect because administering it early for convenience violates the minimum interval guidelines and compromises immunity. Option B is incorrect because a healthy twelve-year-old only requires a two-dose series, making a third dose unnecessary. Option D is incorrect because delaying an additional six months from today unnecessarily postpones protection.

The triad of ipsilateral facial paralysis, ear pain, and vesicles in the auditory canal or auricle is the hallmark of Ramsay Hunt syndrome, which is caused by reactivation of the varicella-zoster virus in the geniculate ganglion. Idiopathic acute Bell palsy also presents with facial paralysis but specifically lacks the vesicular eruption and severe ear pain. Uncomplicated acute otitis externa causes ear pain and canal inflammation but does not cause facial nerve palsy or distinct herpetic vesicles. Severe trigeminal neuralgia flare causes sharp electric facial pain but does not result in facial muscle weakness or vesicular lesions.

Patients receiving biologic disease-modifying antirheumatic drugs are significantly immunosuppressed and must never receive live attenuated vaccines due to the risk of disseminated infection. Option A is incorrect because the recombinant zoster vaccine is inactive and safe for patients on biologics. Option B is incorrect because the inactivated intramuscular influenza vaccine is safe and highly recommended for immunosuppressed patients to prevent severe respiratory illness. Option D is incorrect because the pneumococcal conjugate vaccine is inactive and strongly indicated for older adults on immunosuppressive biologic therapies.

The CDC recommends that adults aged 65 and older who have not previously received a pneumococcal conjugate vaccine should receive either a single dose of PCV20 or a dose of PCV15 followed by PPSV23. When PCV20 is used, no additional doses are required, making option A the most efficient and correct choice. Option B is incorrect because the eight-week interval is reserved for immunocompromised patients; healthy adults should wait one year. Option C is incorrect because a conjugate vaccine should always be administered before PPSV23 if both are indicated. Option D is incorrect because PCV15 and PCV20 are not recommended to be used sequentially in a standard series.

The USPSTF recommends cytology alone every three years for women aged 21 to 29. Routine HPV testing is not recommended for this age group because transient HPV infections are highly prevalent and typically clear spontaneously. Performing co-testing or primary HPV testing in this patient leads to unnecessary colposcopies and potential harm from overtreatment. Deferring all screening until age 25 ignores the established guideline to initiate cytology screening at age 21.

The patient is currently in the core window period of an acute hepatitis B infection. During this specific timeframe, the surface antigen has already been cleared from the bloodstream, but the protective surface antibodies have not yet reached detectable levels. The only serological marker present to indicate the recent acute infection is the core IgM antibody. Option A is incorrect because chronic infection requires the persistent presence of surface antigen. Option B is incorrect because vaccine immunity would show positive surface antibodies and negative core antibodies. Option C is incorrect because a fully resolved infection would demonstrate positive surface antibodies alongside core IgG antibodies, rather than the IgM antibodies seen in this acute window phase.

While high-dose, recombinant, or adjuvanted influenza vaccines are preferred for adults aged 65 and older, the CDC explicitly advises against delaying vaccination if the preferred products are unavailable. In such cases, administering a standard-dose influenza vaccine is the correct clinical decision to ensure the patient receives timely seasonal protection. Option A is incorrect because delaying vaccination leaves the older adult vulnerable during peak influenza season. Option B is inappropriate, as antivirals are not a substitute for seasonal vaccination. Option C is incorrect because the patient is already up to date on pneumococcal vaccines, and routine boosters of PCV20 are not currently recommended.